Panbela Therapeutics Inc. Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
PBLADelisted Stock | USD 2.06 0.11 5.07% |
About 62% of Panbela Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Panbela Therapeutics stock suggests that many investors are alarmed at this time. The current market sentiment, together with Panbela Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Panbela Therapeutics stock news signals to limit their universe of possible portfolio assets.
Panbela |
Panbela Therapeutics Inc. Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
Read at investing.com
Panbela Therapeutics Fundamental Analysis
We analyze Panbela Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Panbela Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Panbela Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Panbela Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Panbela Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Panbela Therapeutics stock to make a market-neutral strategy. Peer analysis of Panbela Therapeutics could also be used in its relative valuation, which is a method of valuing Panbela Therapeutics by comparing valuation metrics with similar companies.
Peers
Panbela Therapeutics Related Equities
REVB | Revelation Biosciences | 25.00 | ||||
CYTO | Altamira Therapeutics | 7.50 | ||||
UNCY | Unicycive Therapeutics | 7.25 | ||||
QNRX | Quoin Pharmaceuticals | 6.67 | ||||
KPRX | Kiora Pharmaceuticals | 5.52 | ||||
SONN | Sonnet Biotherapeutics | 1.56 | ||||
VRAX | Virax Biolabs | 1.02 | ||||
PALI | Palisade Bio | 2.44 | ||||
CDIO | Cardio Diagnostics | 3.23 | ||||
ZVSA | ZyVersa Therapeutics | 3.74 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Panbela Stock
If you are still planning to invest in Panbela Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Panbela Therapeutics' history and understand the potential risks before investing.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |